Eli Lilly Foundayo phase 3 milestone: Can LLY sustain its rally?

Traders Union
All News
Stocks
Eli Lilly jumps 3.49% to $1,410 today

Highlights

Eli Lilly announced its oral GLP-1 drug Foundayo achieved significant improvement in sleep apnea for obese adults in a phase 3 trial.
The company plans to seek U.S. approval for Foundayo in sleep apnea and expand branded access through a self-pay partnership with Hims & Hers Health.
Shares of Eli Lilly rose 3.49% to $1,410, with price expected to consolidate in a $1,368 to $1,453 range and a 68% probability of an upward move.

Sleep apnea results, new partnership bolster demand and commercial reach

Eli Lilly reported that its oral GLP-1 Foundayo (orforglipron) led to significant improvements in sleep apnea in a phase 3 trial, a milestone that enhances the drug's commercial outlook and supports demand expectations, as highlighted by Seeking Alpha. The company is also preparing to file for U.S. regulatory approval of the daily Foundayo pill to treat moderate-to-severe obstructive sleep apnea in adults with obesity, according to CNBC, signaling intent to further expand its market reach in high-burden patient groups. Additionally, Eli Lilly is broadening its distribution through a new partnership with Hims & Hers Health to offer branded Zepbound and Foundayo weight-loss medications at self-pay prices, based on reporting by Investing.com, which may further reinforce product access and visibility.

Resilient above key averages as momentum signals diverge

On the technical front, LLY is trading above the MA-20 at $1,389 and MA-50 at $1,399 on the working timeframe, and remains well above the long-term MA-200 at $1,099. Immediate support is defined by the Ichimoku Kijun at $1,393. Momentum indicators are mixed, with both MACD and ADX generating Sell signals, while RSI is at 48.31 and CCI at –34.64 are neutral, and Stoch RSI sits in the overbought zone. Bull/Bear Power at 7.76 indicates buyers dominate intraday, while the Awesome Oscillator remains neutral. Volatility is moderate, and the price closed near the session’s high after opening with a 6.91 gap.

Consolidation expected unless key levels prompt breakout or reversal

In the short term, the expected trading range for LLY is $1,368 to $1,453. There is a 68% probability of an upward move, while the bearish scenario holds a 32% chance. The baseline scenario anticipates continued consolidation within this zone, with a bullish breakout possible if the upper end is cleared, and downside risk emerging if support at the lower bound fails.

Anton Kharitonov, analyst at Traders Union, views Eli Lilly as holding a cautious but constructive position after recent clinical trial news. He notes technical support remains intact, but mixed indicators warn traders not to chase the move without a clear breakout. Consolidation between $1,368 and $1,453 is likely, with upside only if key resistance is cleared. "Until LLY closes convincingly above $1,453, I remain on the sidelines and await stronger confirmation of trend direction."

Earlier, analysts noted that Eli Lilly’s strong fundamentals and raised guidance were supporting a bullish technical bias, even as short-term signals warned of potential overbought conditions and downside risk. The latest developments—highlighted by key clinical progress, expanded distribution partnerships, and continued technical strength—reinforce the positive outlook for LLY, with near-term attention focused on the $1,368 support level as a potential pivot for continued consolidation or renewed upside.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.